Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU

T. D. Nelin, E. Pena, T. Giacomazzi, S. Lee, J. W. Logan, M. Moallem, R. Bapat, E. G. Shepherd, L. D. Nelin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: We examined data from a contemporary cohort of extreme prematurity (EP) infants admitted to an all-referral Children's Hospital neonatal intensive care unit (NICU) to determine whether prophylactic indomethacin (PI) may continue to benefit these patients. Study Design: An observational study utilizing the small baby ICU data registry that was queried for all EP infants admitted between 2005 and 2014 with documentation of PI use (671 total EP infants; 141 (21%) did not receive PI (control); 530 (79%) received PI (PI). This cohort of EP infants was born at outside hospitals and transferred to our level IV NICU with a mean age on admission of 13 days, well after the PI would have been administered. Results: No difference existed between the control and PI groups in gestational age, birth weight, severity of illness, other in-hospital outcomes or developmental delay. PI infants had a significantly lower mortality rate (P=0.0004), lower relative risk (RR) for mortality 0.52 (95% confidence interval (CI) 0.37 to 0.73, P=0.0001) and lower RR of developing the combined outcome of death or bronchopulmonary dysplasia (RR 0.91, 95% CI 0.85 to 0.98, P=0.012) when compared with the control group. Notably, there was no significant effect of PI on incidence of severe intraventricular hemorrhage or patent ductus arteriosus ligation. Conclusion: PI administration was associated with improved survival in EP infants referred to a level IV Children's Hospital NICU.

Original languageEnglish (US)
Pages (from-to)932-937
Number of pages6
JournalJournal of Perinatology
Volume37
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Extremely Premature Infants
Neonatal Intensive Care Units
Indomethacin
Referral and Consultation
Confidence Intervals
Bronchopulmonary Dysplasia
Patent Ductus Arteriosus
Mortality
Birth Weight
Documentation
Gestational Age
Observational Studies
Ligation
Registries

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Nelin, T. D., Pena, E., Giacomazzi, T., Lee, S., Logan, J. W., Moallem, M., ... Nelin, L. D. (2017). Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU. Journal of Perinatology, 37(8), 932-937. https://doi.org/10.1038/jp.2017.71

Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU. / Nelin, T. D.; Pena, E.; Giacomazzi, T.; Lee, S.; Logan, J. W.; Moallem, M.; Bapat, R.; Shepherd, E. G.; Nelin, L. D.

In: Journal of Perinatology, Vol. 37, No. 8, 01.08.2017, p. 932-937.

Research output: Contribution to journalArticle

Nelin, TD, Pena, E, Giacomazzi, T, Lee, S, Logan, JW, Moallem, M, Bapat, R, Shepherd, EG & Nelin, LD 2017, 'Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU', Journal of Perinatology, vol. 37, no. 8, pp. 932-937. https://doi.org/10.1038/jp.2017.71
Nelin, T. D. ; Pena, E. ; Giacomazzi, T. ; Lee, S. ; Logan, J. W. ; Moallem, M. ; Bapat, R. ; Shepherd, E. G. ; Nelin, L. D. / Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU. In: Journal of Perinatology. 2017 ; Vol. 37, No. 8. pp. 932-937.
@article{7775bc74bc1b4813ba6f38f2f15aa5e2,
title = "Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU",
abstract = "Objective: We examined data from a contemporary cohort of extreme prematurity (EP) infants admitted to an all-referral Children's Hospital neonatal intensive care unit (NICU) to determine whether prophylactic indomethacin (PI) may continue to benefit these patients. Study Design: An observational study utilizing the small baby ICU data registry that was queried for all EP infants admitted between 2005 and 2014 with documentation of PI use (671 total EP infants; 141 (21{\%}) did not receive PI (control); 530 (79{\%}) received PI (PI). This cohort of EP infants was born at outside hospitals and transferred to our level IV NICU with a mean age on admission of 13 days, well after the PI would have been administered. Results: No difference existed between the control and PI groups in gestational age, birth weight, severity of illness, other in-hospital outcomes or developmental delay. PI infants had a significantly lower mortality rate (P=0.0004), lower relative risk (RR) for mortality 0.52 (95{\%} confidence interval (CI) 0.37 to 0.73, P=0.0001) and lower RR of developing the combined outcome of death or bronchopulmonary dysplasia (RR 0.91, 95{\%} CI 0.85 to 0.98, P=0.012) when compared with the control group. Notably, there was no significant effect of PI on incidence of severe intraventricular hemorrhage or patent ductus arteriosus ligation. Conclusion: PI administration was associated with improved survival in EP infants referred to a level IV Children's Hospital NICU.",
author = "Nelin, {T. D.} and E. Pena and T. Giacomazzi and S. Lee and Logan, {J. W.} and M. Moallem and R. Bapat and Shepherd, {E. G.} and Nelin, {L. D.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1038/jp.2017.71",
language = "English (US)",
volume = "37",
pages = "932--937",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU

AU - Nelin, T. D.

AU - Pena, E.

AU - Giacomazzi, T.

AU - Lee, S.

AU - Logan, J. W.

AU - Moallem, M.

AU - Bapat, R.

AU - Shepherd, E. G.

AU - Nelin, L. D.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objective: We examined data from a contemporary cohort of extreme prematurity (EP) infants admitted to an all-referral Children's Hospital neonatal intensive care unit (NICU) to determine whether prophylactic indomethacin (PI) may continue to benefit these patients. Study Design: An observational study utilizing the small baby ICU data registry that was queried for all EP infants admitted between 2005 and 2014 with documentation of PI use (671 total EP infants; 141 (21%) did not receive PI (control); 530 (79%) received PI (PI). This cohort of EP infants was born at outside hospitals and transferred to our level IV NICU with a mean age on admission of 13 days, well after the PI would have been administered. Results: No difference existed between the control and PI groups in gestational age, birth weight, severity of illness, other in-hospital outcomes or developmental delay. PI infants had a significantly lower mortality rate (P=0.0004), lower relative risk (RR) for mortality 0.52 (95% confidence interval (CI) 0.37 to 0.73, P=0.0001) and lower RR of developing the combined outcome of death or bronchopulmonary dysplasia (RR 0.91, 95% CI 0.85 to 0.98, P=0.012) when compared with the control group. Notably, there was no significant effect of PI on incidence of severe intraventricular hemorrhage or patent ductus arteriosus ligation. Conclusion: PI administration was associated with improved survival in EP infants referred to a level IV Children's Hospital NICU.

AB - Objective: We examined data from a contemporary cohort of extreme prematurity (EP) infants admitted to an all-referral Children's Hospital neonatal intensive care unit (NICU) to determine whether prophylactic indomethacin (PI) may continue to benefit these patients. Study Design: An observational study utilizing the small baby ICU data registry that was queried for all EP infants admitted between 2005 and 2014 with documentation of PI use (671 total EP infants; 141 (21%) did not receive PI (control); 530 (79%) received PI (PI). This cohort of EP infants was born at outside hospitals and transferred to our level IV NICU with a mean age on admission of 13 days, well after the PI would have been administered. Results: No difference existed between the control and PI groups in gestational age, birth weight, severity of illness, other in-hospital outcomes or developmental delay. PI infants had a significantly lower mortality rate (P=0.0004), lower relative risk (RR) for mortality 0.52 (95% confidence interval (CI) 0.37 to 0.73, P=0.0001) and lower RR of developing the combined outcome of death or bronchopulmonary dysplasia (RR 0.91, 95% CI 0.85 to 0.98, P=0.012) when compared with the control group. Notably, there was no significant effect of PI on incidence of severe intraventricular hemorrhage or patent ductus arteriosus ligation. Conclusion: PI administration was associated with improved survival in EP infants referred to a level IV Children's Hospital NICU.

UR - http://www.scopus.com/inward/record.url?scp=85028620337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028620337&partnerID=8YFLogxK

U2 - 10.1038/jp.2017.71

DO - 10.1038/jp.2017.71

M3 - Article

C2 - 28617424

AN - SCOPUS:85028620337

VL - 37

SP - 932

EP - 937

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 8

ER -